Tokyo Tape
Sign in
← Carna Biosciences

Annual report

4572.TEDINET S100QFB8
Period2022-01-01 → 2022-12-31
Filed2023-03-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 137
MetricValuePeriodScopeSource row
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales
Revenue¥2.0bn2021-01-01 → 2021-12-31Cons.Net sales
Revenue¥1.1bn2020-01-01 → 2020-12-31dCons.Net sales (5-year summary)
Revenue¥3.2bn2019-01-01 → 2019-12-31dCons.Net sales (5-year summary)
Revenue¥755m2018-01-01 → 2018-12-31dCons.Net sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31Cons.Operating income
Operating income−¥531m2021-01-01 → 2021-12-31Cons.Operating income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥523m2021-01-01 → 2021-12-31Cons.Ordinary income
Ordinary income−¥1.1bn2020-01-01 → 2020-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥957m2019-01-01 → 2019-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥1.3bn2022-01-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥532m2021-01-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥534m2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥828m2019-01-01 → 2019-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2018-01-01 → 2018-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss
Net income−¥534m2021-01-01 → 2021-12-31Cons.Profit loss
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥5.4bnat 2021-12-31Cons.Assets
Total assets¥4.8bnat 2020-12-31dCons.Total assets (5-year summary)
Total assets¥5.4bnat 2019-12-31dCons.Total assets (5-year summary)
Total assets¥1.8bnat 2018-12-31dCons.Total assets (5-year summary)
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Total liabilities¥1.1bnat 2021-12-31Cons.Liabilities
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥4.3bnat 2021-12-31Cons.Net assets
Net assets / equity¥3.8bnat 2020-12-31dCons.Net assets
Net assets / equity¥3.9bnat 2019-12-31dCons.Net assets (5-year summary)
Net assets / equity¥887mat 2018-12-31dCons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥3.8bnat 2021-12-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.8bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.3bnat 2020-12-31dCons.Cash and cash equivalents
Cash & equivalents¥4.9bnat 2019-12-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥1.4bnat 2018-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥708m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.5bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.3bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.5bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2018-01-01 → 2018-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥126m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥42m2021-01-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥70m2020-01-01 → 2020-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥41m2019-01-01 → 2019-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥58m2018-01-01 → 2018-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥367m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.1bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥724m2020-01-01 → 2020-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.1bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥688m2018-01-01 → 2018-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-90.332020-01-01 → 2020-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥76.052019-01-01 → 2019-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-125.022018-01-01 → 2018-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥74.512019-01-01 → 2019-12-31dCons.Diluted earnings per share (5-year summary)
Net assets per share¥255.04at 2022-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥323.54at 2021-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥308.05at 2020-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥329.86at 2019-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥86.83at 2018-12-31dCons.Net assets per share (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio79.0%at 2020-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio71.5%at 2019-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio49.7%at 2018-12-31dCons.Equity to asset ratio (5-year summary)
ROE35.1%2019-01-01 → 2019-12-31dCons.Rate of return on equity (5-year summary)
Employees65at 2022-12-31Cons.Number of employees
Employees64at 2021-12-31Cons.Number of employees
Employees64at 2020-12-31dCons.Number of employees
Employees63at 2019-12-31dCons.Number of employees
Employees62at 2018-12-31dCons.Number of employees
Revenue¥1.2bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥1.9bn2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥1.0bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥3.1bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥641m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥558m2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥1.4bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥549m2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥874m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.4bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥558m2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥1.4bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥556m2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥746m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.0bnat 2022-12-31StandaloneAssets
Total assets¥5.3bnat 2021-12-31StandaloneAssets
Total assets¥4.7bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.3bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥607mat 2022-12-31StandaloneLiabilities
Total liabilities¥1.1bnat 2021-12-31StandaloneLiabilities
Net assets / equity¥3.4bnat 2022-12-31StandaloneNet assets
Net assets / equity¥4.2bnat 2021-12-31StandaloneNet assets
Net assets / equity¥3.7bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥3.8bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥900mat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.1bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥3.6bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-103.22022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-43.832021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-91.842020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥68.472019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-123.852018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥67.082019-01-01 → 2019-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥240.82at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥314.45at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥301.39at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥323.68at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥88.07at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio84.6%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.9%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio50.1%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE32.0%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued14,218,300at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,313,400at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued12,407,100at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,654,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued10,139,600at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees62at 2022-12-31StandaloneNumber of employees
Employees61at 2021-12-31StandaloneNumber of employees
Employees61at 2020-12-31dStandaloneNumber of employees
Employees60at 2019-12-31dStandaloneNumber of employees
Employees58at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 42
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥3.2bn
Drug Discovery Businessreportable segmentcapex2022-01-01 → 2022-12-31¥68m
Drug Discovery Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥13m
Drug Discovery Businessreportable segmentemployeesat 2022-12-3134 pure
Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥286m
Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥286m
Drug Discovery Businessreportable segmentsegment assetsat 2022-12-31¥373m
Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.7bn
Drug Discovery Support Businessreportable segmentcapex2022-01-01 → 2022-12-31¥58m
Drug Discovery Support Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥21m
Drug Discovery Support Businessreportable segmentemployeesat 2022-12-3123 pure
Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥1.1bn
Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥1.1bn
Drug Discovery Support Businessreportable segmentsegment assetsat 2022-12-31¥685m
Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥453m
—segment totalcapex2022-01-01 → 2022-12-31¥126m
—segment totaldepreciation2022-01-01 → 2022-12-31¥34m
—segment totalrevenue2022-01-01 → 2022-12-31¥1.4bn
—segment totalrevenue external2022-01-01 → 2022-12-31¥1.4bn
—segment totalsegment assetsat 2022-12-31¥1.1bn
—segment totalsegment profit2022-01-01 → 2022-12-31−¥1.3bn
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥3.7bn
Drug Discovery Businessreportable segmentcapex2021-01-01 → 2021-12-31¥14m
Drug Discovery Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥5m
Drug Discovery Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥1.1bn
Drug Discovery Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥1.1bn
Drug Discovery Businessreportable segmentsegment assetsat 2021-12-31¥1.2bn
Drug Discovery Businessreportable segmentsegment profit2021-01-01 → 2021-12-31−¥820m
Drug Discovery Support Businessreportable segmentcapex2021-01-01 → 2021-12-31¥12m
Drug Discovery Support Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥15m
Drug Discovery Support Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥890m
Drug Discovery Support Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥890m
Drug Discovery Support Businessreportable segmentsegment assetsat 2021-12-31¥497m
Drug Discovery Support Businessreportable segmentsegment profit2021-01-01 → 2021-12-31¥289m
—segment totalcapex2021-01-01 → 2021-12-31¥26m
—segment totaldepreciation2021-01-01 → 2021-12-31¥19m
—segment totalrevenue2021-01-01 → 2021-12-31¥2.0bn
—segment totalrevenue external2021-01-01 → 2021-12-31¥2.0bn
—segment totalsegment assetsat 2021-12-31¥1.7bn
—segment totalsegment profit2021-01-01 → 2021-12-31−¥531m
Drug Discovery Businessreportable segmentemployeesat 2022-12-3133 pure
Drug Discovery Support Businessreportable segmentemployeesat 2022-12-3121 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,303
ItemContextValueUnit
Total changes of items during the periodPrior1YearDuration_ForeignCurrencyTranslationAdjustmentMember16396000JPY
Total changes of items during the periodPrior1YearDuration_ValuationAndTranslationAdjustmentsMember23498000JPY
Total changes of items during the periodPrior1YearDuration_SubscriptionRightsToSharesMember6289000JPY
Total changes of items during the periodPrior1YearDuration491561000JPY
Net assetsPrior1YearInstant_ValuationDifferenceOnAvailableForSaleSecuritiesMember-630000JPY
Net assetsPrior1YearInstant_DeferredGainsOrLossesOnHedgesMember6578000JPY
Net assetsPrior1YearInstant_ForeignCurrencyTranslationAdjustmentMember7841000JPY
Net assetsPrior1YearInstant_ValuationAndTranslationAdjustmentsMember13789000JPY
Net assetsPrior1YearInstant_SubscriptionRightsToSharesMember9840000JPY
Net assetsPrior1YearInstant4315572000JPY
Net assetsPrior1YearInstant_CapitalStockMember1056953000JPY
Net assetsPrior1YearInstant_CapitalSurplusMember4808163000JPY
Net assetsPrior1YearInstant_RetainedEarningsMember-1572951000JPY
Net assetsPrior1YearInstant_TreasuryStockMember-222000JPY
Net assetsPrior1YearInstant_ShareholdersEquityMember4291942000JPY
Issuance of new sharesCurrentYearDuration_CapitalStockMember22243000JPY
Issuance of new sharesCurrentYearDuration_CapitalSurplusMember22243000JPY
Issuance of new sharesCurrentYearDuration_ShareholdersEquityMember44487000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_CapitalStockMember303049000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_CapitalSurplusMember303049000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_ShareholdersEquityMember606098000JPY
Profit loss attributable to owners of parentCurrentYearDuration_RetainedEarningsMember-1349539000JPY
Profit loss attributable to owners of parentCurrentYearDuration_ShareholdersEquityMember-1349539000JPY
Total changes of items during the periodCurrentYearDuration_CapitalStockMember325292000JPY
Total changes of items during the periodCurrentYearDuration_CapitalSurplusMember325292000JPY
Total changes of items during the periodCurrentYearDuration_RetainedEarningsMember-1349539000JPY
Total changes of items during the periodCurrentYearDuration_TreasuryStockMember－JPY
Total changes of items during the periodCurrentYearDuration_ShareholdersEquityMember-698954000JPY
Net assetsCurrentYearInstant_CapitalStockMember1382246000JPY
Net assetsCurrentYearInstant_CapitalSurplusMember5133456000JPY
Net assetsCurrentYearInstant_RetainedEarningsMember-2922490000JPY
Net assetsCurrentYearInstant_TreasuryStockMember-222000JPY
Net assetsCurrentYearInstant_ShareholdersEquityMember3592988000JPY
Net assetsPrior1YearInstant_ValuationDifferenceOnAvailableForSaleSecuritiesMember-630000JPY
Net assetsPrior1YearInstant_DeferredGainsOrLossesOnHedgesMember6578000JPY
Net assetsPrior1YearInstant_ForeignCurrencyTranslationAdjustmentMember7841000JPY
Net assetsPrior1YearInstant_ValuationAndTranslationAdjustmentsMember13789000JPY
Net assetsPrior1YearInstant_SubscriptionRightsToSharesMember9840000JPY
Net assetsPrior1YearInstant4315572000JPY
Issuance of new sharesCurrentYearDuration44487000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration606098000JPY
Profit loss attributable to owners of parentCurrentYearDuration-1349539000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ValuationDifferenceOnAvailableForSaleSecuritiesMember-1742000JPY
Net changes of items other than shareholders equityCurrentYearDuration_DeferredGainsOrLossesOnHedgesMember-5962000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ForeignCurrencyTranslationAdjustmentMember25384000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ValuationAndTranslationAdjustmentsMember17678000JPY
Net changes of items other than shareholders equityCurrentYearDuration_SubscriptionRightsToSharesMember7548000JPY
Net changes of items other than shareholders equityCurrentYearDuration25226000JPY
Total changes of items during the periodCurrentYearDuration_ValuationDifferenceOnAvailableForSaleSecuritiesMember-1742000JPY
Total changes of items during the periodCurrentYearDuration_DeferredGainsOrLossesOnHedgesMember-5962000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-12-31pass
balance sheet identitynon_consolidated 2021-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-12-31pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-01-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass